IDEXX LABORATORIES INC /DE Selling and Marketing Expense
IDEXX LABORATORIES INC /DE (IDXX) reported Selling and Marketing Expense of $171.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE selling and marketing expense for the quarter ending 2026-06-30 was $171.28M, a 6.31% increase year-over-year.
- IDEXX LABORATORIES INC /DE selling and marketing expense for the quarter ending 2026-03-31 was $175.25M, a 12.18% increase year-over-year.
- IDEXX LABORATORIES INC /DE selling and marketing expense for the quarter ending 2025-12-31 was $167.06M, a 11.29% increase year-over-year.
- IDEXX LABORATORIES INC /DE selling and marketing expense for the quarter ending 2025-09-30 was $159.16M, a 8.80% increase year-over-year.
- IDEXX LABORATORIES INC /DE selling and marketing expense for fiscal 2025 was $643.55M, a 9.35% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE selling and marketing expense for fiscal 2024 was $588.51M, a 3.96% increase from fiscal 2023.
- IDEXX LABORATORIES INC /DE selling and marketing expense for fiscal 2023 was $566.07M, a 7.92% increase from fiscal 2022.
- IDEXX LABORATORIES INC /DE selling and marketing expense for fiscal 2022 was $524.50M, a 7.76% increase from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $171.28M 10-Q · filed 2026-08-04 | $346.53M 10-Q · filed 2026-08-04 | $513.59M derived: sum of 3 quarters · filed 2026-08-04 | $672.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $175.25M 10-Q · filed 2026-05-05 | $342.31M derived: sum of 2 quarters · filed 2026-05-05 | $501.47M derived: sum of 3 quarters · filed 2026-05-05 | $662.57M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $167.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $326.22M derived: sum of 2 quarters · filed 2026-02-20 | $487.32M derived: sum of 3 quarters · filed 2026-08-04 | $643.55M 10-K · filed 2026-02-20 |
| 2025-09-30 | $159.16M 10-Q · filed 2025-11-03 | $320.26M derived: sum of 2 quarters · filed 2026-08-04 | $476.49M 10-Q · filed 2025-11-03 | $626.60M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $161.11M 10-Q · filed 2026-08-04 | $317.33M 10-Q · filed 2026-08-04 | $467.44M derived: sum of 3 quarters · filed 2026-08-04 | $613.72M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $156.22M 10-Q · filed 2026-05-05 | $306.33M derived: sum of 2 quarters · filed 2026-05-05 | $452.61M derived: sum of 3 quarters · filed 2026-05-05 | $595.28M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $150.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $296.39M derived: sum of 2 quarters · filed 2026-02-20 | $439.05M derived: sum of 3 quarters · filed 2026-02-20 | $588.51M 10-K · filed 2026-02-20 |
| 2024-09-30 | $146.28M 10-Q · filed 2025-11-03 | $288.95M derived: sum of 2 quarters · filed 2025-11-03 | $438.40M 10-Q · filed 2025-11-03 | $580.43M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $142.66M 10-Q · filed 2025-08-04 | $292.12M 10-Q · filed 2025-08-04 | $434.15M derived: sum of 3 quarters · filed 2026-02-20 | $569.85M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $149.45M 10-Q · filed 2025-05-01 | $291.49M derived: sum of 2 quarters · filed 2026-02-20 | $427.18M derived: sum of 3 quarters · filed 2026-02-20 | $567.72M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $142.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $277.73M derived: sum of 2 quarters · filed 2026-02-20 | $418.26M derived: sum of 3 quarters · filed 2026-02-20 | $566.07M 10-K · filed 2026-02-20 |
| 2023-09-30 | $135.70M 10-Q · filed 2024-10-31 | $276.23M derived: sum of 2 quarters · filed 2024-10-31 | $424.03M 10-Q · filed 2024-10-31 | $555.97M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $140.53M 10-Q · filed 2024-08-06 | $288.34M 10-Q · filed 2024-08-06 | $420.27M derived: sum of 3 quarters · filed 2025-02-21 | $550.29M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $147.80M 10-Q · filed 2024-05-01 | $279.74M derived: sum of 2 quarters · filed 2025-02-21 | $409.76M derived: sum of 3 quarters · filed 2025-02-21 | $540.02M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $131.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $261.96M derived: sum of 2 quarters · filed 2025-02-21 | $392.21M derived: sum of 3 quarters · filed 2025-02-21 | $524.50M 10-K · filed 2025-02-21 |
| 2022-09-30 | $130.02M 10-Q · filed 2023-11-01 | $260.28M derived: sum of 2 quarters · filed 2023-11-01 | $392.57M 10-Q · filed 2023-11-01 | $521.03M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $130.26M 10-Q · filed 2023-08-01 | $262.55M 10-Q · filed 2023-08-01 | $391.01M derived: sum of 3 quarters · filed 2024-02-22 | $515.44M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $132.29M 10-Q · filed 2023-05-02 | $260.75M derived: sum of 2 quarters · filed 2024-02-22 | $385.18M derived: sum of 3 quarters · filed 2024-02-22 | $504.22M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $128.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $252.89M derived: sum of 2 quarters · filed 2024-02-22 | $371.92M derived: sum of 3 quarters · filed 2024-02-22 | $486.74M 10-K · filed 2024-02-22 |
| 2021-09-30 | $124.43M 10-Q · filed 2022-11-01 | $243.47M derived: sum of 2 quarters · filed 2022-11-01 | $358.28M 10-Q · filed 2022-11-01 | $474.19M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-06-30 | $119.03M 10-Q · filed 2022-08-02 | $233.84M 10-Q · filed 2022-08-02 | $349.75M derived: sum of 3 quarters · filed 2023-02-16 | $457.95M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-03-31 | $114.81M 10-Q · filed 2022-05-04 | $230.72M derived: sum of 2 quarters · filed 2023-02-16 | $338.92M derived: sum of 3 quarters · filed 2023-02-16 | $433.10M derived: sum of 4 quarters · filed 2023-02-16 |
| 2020-12-31 | $115.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $224.11M derived: sum of 2 quarters · filed 2023-02-16 | $318.29M derived: sum of 3 quarters · filed 2023-02-16 | $434.44M 10-K · filed 2023-02-16 |
| 2020-09-30 | $108.20M 10-Q · filed 2021-11-02 | $202.38M derived: sum of 2 quarters · filed 2021-11-02 | $318.53M 10-Q · filed 2021-11-02 | $424.22M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-30 | $94.18M 10-Q · filed 2021-07-30 | $210.32M 10-Q · filed 2021-07-30 | $316.02M derived: sum of 3 quarters · filed 2022-02-16 | $420.57M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-31 | $116.14M 10-Q · filed 2021-05-04 | $221.84M derived: sum of 2 quarters · filed 2022-02-16 | $326.39M derived: sum of 3 quarters · filed 2022-02-16 | $427.75M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-31 | $105.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $210.25M derived: sum of 2 quarters · filed 2022-02-16 | $311.61M derived: sum of 3 quarters · filed 2022-02-16 | $418.19M 10-K · filed 2022-02-16 |
| 2019-09-30 | $104.55M 10-Q · filed 2020-10-29 | $205.91M derived: sum of 2 quarters · filed 2020-10-29 | $312.50M 10-Q · filed 2020-10-29 | $408.40M derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-06-30 | $101.36M 10-Q · filed 2020-07-31 | $207.95M 10-Q · filed 2020-07-31 | $303.85M derived: sum of 3 quarters · filed 2021-02-12 | $399.00M derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-03-31 | $106.58M 10-Q · filed 2020-04-30 | $202.49M derived: sum of 2 quarters · filed 2021-02-12 | $297.63M derived: sum of 3 quarters · filed 2021-02-12 | $393.89M derived: sum of 4 quarters · filed 2021-02-12 |
| 2018-12-31 | $95.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $191.05M derived: sum of 2 quarters · filed 2021-02-12 | $287.31M derived: sum of 3 quarters · filed 2021-02-12 | $387.41M 10-K · filed 2021-02-12 |
| 2018-09-30 | $95.15M 10-Q · filed 2019-10-31 | $191.40M derived: sum of 2 quarters · filed 2019-10-31 | $291.50M 10-Q · filed 2019-10-31 | $382.04M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-06-30 | $96.25M 10-Q · filed 2019-08-01 | $196.36M 10-Q · filed 2019-08-01 | $286.89M derived: sum of 3 quarters · filed 2020-02-14 | $375.71M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-03-31 | $100.10M 10-Q · filed 2019-05-01 | $190.64M derived: sum of 2 quarters · filed 2020-02-14 | $279.46M derived: sum of 3 quarters · filed 2020-02-14 | $367.15M derived: sum of 4 quarters · filed 2020-02-14 |
| 2017-12-31 | $90.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $179.36M derived: sum of 2 quarters · filed 2020-02-14 | $267.05M derived: sum of 3 quarters · filed 2020-02-14 | $354.29M 10-K · filed 2020-02-14 |
| 2017-09-30 | $88.82M 10-Q · filed 2018-11-01 | $176.51M derived: sum of 2 quarters · filed 2018-11-01 | $263.75M 10-Q · filed 2018-11-01 | $344.36M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-06-30 | $87.69M 10-Q · filed 2018-08-01 | $174.94M 10-Q · filed 2018-08-01 | $255.54M derived: sum of 3 quarters · filed 2019-02-15 | $335.51M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-03-31 | $87.24M 10-Q · filed 2018-05-04 | $167.85M derived: sum of 2 quarters · filed 2019-02-15 | $247.82M derived: sum of 3 quarters · filed 2019-02-15 | $324.47M derived: sum of 4 quarters · filed 2019-02-15 |
| 2016-12-31 | $80.61M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $160.58M derived: sum of 2 quarters · filed 2019-02-15 | $237.23M derived: sum of 3 quarters · filed 2019-02-15 | $317.06M 10-K · filed 2019-02-15 |
| 2016-09-30 | $79.97M 10-Q · filed 2017-10-31 | $156.62M derived: sum of 2 quarters · filed 2017-10-31 | $236.45M 10-Q · filed 2017-10-31 | $312.95M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $76.65M 10-Q · filed 2017-08-01 | $156.48M 10-Q · filed 2017-08-01 | $232.98M derived: sum of 3 quarters · filed 2018-02-16 | $306.08M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $79.83M 10-Q · filed 2017-04-28 | $156.32M derived: sum of 2 quarters · filed 2018-02-16 | $229.43M derived: sum of 3 quarters · filed 2018-02-16 | $304.65M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $76.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $149.60M derived: sum of 2 quarters · filed 2018-02-16 | $224.82M derived: sum of 3 quarters · filed 2018-02-16 | $299.95M 10-K · filed 2018-02-16 |
| 2015-09-30 | $73.11M 10-Q · filed 2016-11-01 | $148.32M derived: sum of 2 quarters · filed 2016-11-01 | $223.46M 10-Q · filed 2016-11-01 | $300.70M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $75.22M 10-Q · filed 2016-08-02 | $150.35M 10-Q · filed 2016-08-02 | $227.59M derived: sum of 3 quarters · filed 2017-02-17 | $298.19M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $75.14M 10-Q · filed 2016-04-29 | $152.37M derived: sum of 2 quarters · filed 2017-02-17 | $222.98M derived: sum of 3 quarters · filed 2017-02-17 | $291.00M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $77.24M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $147.84M derived: sum of 2 quarters · filed 2017-02-17 | $215.86M derived: sum of 3 quarters · filed 2017-02-17 | $283.71M 10-K · filed 2017-02-17 |
| 2014-09-30 | $70.60M 10-Q · filed 2015-10-28 | $138.62M derived: sum of 2 quarters · filed 2015-10-28 | $206.47M 10-Q · filed 2015-10-28 | $270.32M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-06-30 | $68.02M 10-Q · filed 2015-07-30 | $135.87M 10-Q · filed 2015-07-30 | $199.72M derived: sum of 3 quarters · filed 2016-02-17 | $259.80M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-03-31 | $67.85M 10-Q · filed 2015-04-28 | $131.70M derived: sum of 2 quarters · filed 2016-02-17 | $191.78M derived: sum of 3 quarters · filed 2016-02-17 | $249.67M derived: sum of 4 quarters · filed 2016-02-17 |
| 2013-12-31 | $63.85M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-17 | $123.93M derived: sum of 2 quarters · filed 2016-02-17 | $181.83M derived: sum of 3 quarters · filed 2016-02-17 | $243.49M 10-K · filed 2016-02-17 |
| 2013-09-30 | $60.08M 10-Q · filed 2014-10-24 | $117.97M derived: sum of 2 quarters · filed 2014-10-24 | $179.64M 10-Q · filed 2014-10-24 | $230.10M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-06-30 | $57.90M 10-Q · filed 2014-07-25 | $117.29M 10-Q · filed 2014-07-25 | $170.02M derived: sum of 3 quarters · filed 2015-02-17 | $222.08M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-03-31 | $59.40M 10-Q · filed 2014-04-25 | $112.12M derived: sum of 2 quarters · filed 2015-02-17 | $164.19M derived: sum of 3 quarters · filed 2015-02-17 | $218.73M derived: sum of 4 quarters · filed 2015-02-17 |
| 2012-12-31 | $52.72M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $104.79M derived: sum of 2 quarters · filed 2015-02-17 | $159.33M derived: sum of 3 quarters · filed 2015-02-17 | $216.96M 10-K · filed 2015-02-17 |
| 2012-09-30 | $52.07M 10-Q · filed 2013-10-22 | $106.61M derived: sum of 2 quarters · filed 2013-10-22 | $164.24M 10-Q · filed 2013-10-22 | $216.45M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-06-30 | $54.54M 10-Q · filed 2013-07-23 | $112.17M 10-Q · filed 2013-07-23 | $164.38M derived: sum of 3 quarters · filed 2014-02-18 | $215.06M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-03-31 | $57.63M 10-Q · filed 2013-04-23 | $109.84M derived: sum of 2 quarters · filed 2014-02-18 | $160.52M derived: sum of 3 quarters · filed 2014-02-18 | $211.50M derived: sum of 4 quarters · filed 2014-02-18 |
| 2011-12-31 | $52.21M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-18 | $102.89M derived: sum of 2 quarters · filed 2014-02-18 | $153.87M derived: sum of 3 quarters · filed 2014-02-18 | $204.85M 10-K · filed 2014-02-18 |
| 2011-09-30 | $50.68M 10-Q · filed 2012-10-19 | $101.66M derived: sum of 2 quarters · filed 2012-10-19 | $152.64M 10-Q · filed 2012-10-19 | $199.20M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $50.97M 10-Q · filed 2012-07-20 | $101.96M 10-Q · filed 2012-07-20 | $148.52M derived: sum of 3 quarters · filed 2013-02-19 | $193.00M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $50.98M 10-Q · filed 2012-04-20 | $97.54M derived: sum of 2 quarters · filed 2013-02-19 | $142.03M derived: sum of 3 quarters · filed 2013-02-19 | $186.19M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $46.56M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $91.04M derived: sum of 2 quarters · filed 2013-02-19 | $135.21M derived: sum of 3 quarters · filed 2013-02-19 | $179.63M 10-K · filed 2013-02-19 |
| 2010-09-30 | $44.49M 10-Q · filed 2011-10-21 | $88.65M derived: sum of 2 quarters · filed 2011-10-21 | $133.07M 10-Q · filed 2011-10-21 | $176.45M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | $44.17M 10-Q · filed 2011-07-22 | $88.58M 10-Q · filed 2011-07-22 | $131.97M derived: sum of 3 quarters · filed 2012-02-17 | $173.47M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | $44.42M 10-Q · filed 2011-04-21 | $87.80M derived: sum of 2 quarters · filed 2012-02-17 | $129.30M derived: sum of 3 quarters · filed 2012-02-17 | $171.18M derived: sum of 4 quarters · filed 2012-02-17 |
| 2009-12-31 | $43.38M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $84.89M derived: sum of 2 quarters · filed 2012-02-17 | $126.76M derived: sum of 3 quarters · filed 2012-02-17 | $167.75M 10-K · filed 2012-02-17 |
| 2009-09-30 | $41.50M 10-Q · filed 2010-10-22 | $83.38M derived: sum of 2 quarters · filed 2010-10-22 | $124.36M 10-Q · filed 2010-10-22 | |
| 2009-06-30 | $41.88M 10-Q · filed 2010-07-23 | $82.86M 10-Q · filed 2010-07-23 | ||
| 2008-12-31 | $169.96M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |